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There are few data on the molecular pathogenesis of
cutaneous T cell lymphomas. A recent allelotyping
study by our group identi®ed frequent allelic loss on
9p, 10q, and 17p including losses on 9p21 in 16% of
patients with mycosis fungoides and 46% with
Sezary syndrome. The P15 and P16 genes are intri-
cately linked on 9p21 and can be inactivated in mela-
noma and non-Hodgkin's lymphoma. We have
therefore studied 76 patients with either mycosis fun-
goides or Sezary syndrome for abnormalities of these
genes. DNA samples were analyzed for loss of het-
erozygosity, homozygous deletion, intragenic muta-
tions, and promoter methylation. In addition P15
and P16 protein expression was assessed.
Microsatellite analysis was informative in 73 of 76
cases: allelic loss on 9p21 was identi®ed in 18 patients
(25%), including 12 of 57 with mycosis fungoides
(21%) and six of 16 with Sezary syndrome (37%).
Single strand conformation polymorphism analysis
of the entire coding regions of both genes did not
identify any mutations, although two polymorphisms
were identi®ed including C613A, which has not pre-
viously been described. P15 and P16 gene promoter
methylation was found in 45% and 29% of patients,
respectively. Furthermore aberrant P15 protein
expression was detected in 85% of patients analyzed
with P15 gene abnormalities and abnormal P16
expression in 59% with P16 gene abnormalities.
These abnormalities were not dependent on cuta-
neous stage of disease. This study suggests that
abnormalities of the P15 and P16 genes are common
in both early and advanced stages of mycosis fun-
goides and Sezary syndrome and that these genes
may be inactivated by allelic loss and aberrant pro-
moter methylation. Key words: chromosome 9/cutaneous
T cell lymphoma/P15 and P16 genes. J Invest Dermatol
118:493±499, 2002
P
rimary cutaneous T cell lymphomas (CTCL) consist of
mycosis fungoides, Sezary syndrome, and related variants
(Edelson, 1980). Mycosis fungoides presents with
cutaneous patches and plaques that may progress to
tumor stage disease or erythroderma (Willemze et al,
1997; Zackheim et al, 1999) whereas Sezary syndrome is
characterized by erythroderma, peripheral lymphadenopathy, more
than 5% circulating atypical lymphocytes (Sezary cells), and a
peripheral blood T cell clone as demonstrated by T cell receptor
(TCR) gene analysis (Russell-Jones and Whittaker, 1999).
The molecular pathogenesis of both mycosis fungoides and
Sezary syndrome is still poorly understood. Previous cytogenetic
studies have not identi®ed any characteristic translocations in
CTCL although nonrandom clonal chromosomal abnormalities
have been detected, many of which involve complex structural
rearrangements of multiple chromosomes. A study of 11 patients
with CTCL using comparative genomic hybridization found
chromosomal losses were more frequent than gains. Abnormal
patterns were identi®ed in six patients with frequent losses on
chromosomes 10, 13, and 17. Three patients had abnormalities
involving chromosome 9, one of which involved a deletion in the
region of 9p21 (Karenko et al, 1999). Rearrangements involving 9p
were also identi®ed in three of six patients with CTCL (Berger et
al, 1988) and more recently loss of heterozygosity (LOH) at 9p21
was detected in seven of 11 cases of primary cutaneous CD30-
positive large cell anaplastic lymphoma with loss of p16 protein in
two of these (Boni et al, 2000). Furthermore a recent allelotyping
study in CTCL by our group identi®ed frequent allelic loss on 9p,
10q, and 17p including losses on 9p21 in 16% of patients with
mycosis fungoides and 46% with Sezary syndrome (Scarisbrick et al,
2001). These ®ndings suggest that 9p21 harbours one or more
tumor suppressor genes that are important in the pathogenesis of
CTCL and P15 and P16 are likely candidate genes.
The P16 gene encodes an 18.1 kDa nuclear protein that blocks
cell cycle progression at the G1/S transition by binding to cyclin-
dependent kinase 4 (CDK4) and CDK6 thereby preventing their
ability to phosphorylate the retinoblastoma protein (Serrano et al,
1993). Loss of function is associated with loss of this inhibitory
effect and could potentially lead to uncontrolled cell growth
(Serrano et al, 1993; Kamb et al, 1994). The P15 gene is located 25
kb centromeric to the P16 gene and encodes a nuclear protein
(p15) that has structural homology to p16 and also has CDK4 and
CDK6 inhibitor activity. Initial studies found that P15 and P16
gene inactivation was frequently due to homozygous deletion and
intragenic mutations were rarely identi®ed (Ogawa et al, 1994;
Cairns et al, 1995). Furthermore several studies identi®ed LOH
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involving deletion of one or both genes with no detectable
mutation on the remaining allele (Ogawa et al, 1994; Takeuchi et al,
1995). This observation raised questions about the mechanism of
gene inactivation and it was suggested that either an epigenetic
mechanism produced inactivation of the remaining allele or that a
gene dosage effect might be critically important for P15 and P16
gene function, such that loss of one allele could exert a dominant
negative effect. Aberrant methylation of CpG islands within P15
and P16 gene promoter sites producing transcriptional silencing was
subsequently identi®ed as an alternative mechanism of P15 and P16
gene inactivation in sporadic malignancies (Gonzalez-Zulueta et al,
1995; Herman et al, 1995; Merlo et al, 1995).
Germline mutations of P15 and P16 genes are found in some
cases of familial melanoma (Hussussian et al, 1994) and homozygous
deletions have been found in various sporadic malignancies
including lymphoma (Gombart et al, 1995; Otsuki et al, 1995;
Heyman et al, 1996) and speci®cally more aggressive forms of nodal
non-Hodgkin's lymphoma (Pinyol et al, 1997, 1998; Elenitoba-
Johnson et al, 1998; Villuendas et al, 1998). These ®ndings have led
us to perform a comprehensive study of abnormalities of the P15
and P16 genes to determine if gene inactivation is important in the
pathogenesis of CTCL. Samples were analyzed for LOH,
homozygous deletions, intragenic mutations, and aberrant pro-
moter methylation. In addition P15 and P16 protein expression was
studied.
MATERIALS AND METHODS
Sample selection Seventy-six patients with primary CTCL were
selected for this study, consisting of 58 mycosis fungoides patients with
different cutaneous stages of disease: T1, 14; T2, 18; T3, 20; and T4, 6;
this included IA, 14; IB, 15; IIA, 3; IIB, 14; III, 2; and IVA, 10
(Lamberg et al, 1984). All patients had skin lesions consistent with a
clinical diagnosis of mycosis fungoides, compatible skin histology, and a
T cell clone in lesional skin demonstrated by TCR gene analysis. These
tumor samples were chosen because either southern blot or single strand
conformational polymorphism polymerase chain reaction (PCR) based
TCR gene analysis (Whittaker et al, 1991; Fraser-Andrews et al, 2000)
had previously demonstrated a clonal population in lesional skin, which
was absent from the peripheral blood or lymph node. Furthermore only
those samples with a large dominant clone were selected for this study: a
large dominant clone was determined by measuring the signal intensity
of the discrete band, using an Image Master Scanning Densitometer
(Amersham Pharmacia, U.K.) with Image Master Software (Amersham
Pharmacia), and only samples with a signal intensity of more than 50% in
the discrete band compared to the background smear were considered to
contain a large dominant clone. Eighteen patients with Sezary syndrome
were also selected and the diagnostic criteria included erythroderma,
peripheral lymphadenopathy, the presence of circulating Sezary cells, and
a large dominant peripheral blood T cell clone.
Microsatellite analysis requires comparison between tumor and normal
DNA from individual patients. In most patients with mycosis fungoides
tumor DNA was extracted from lesional skin and normal control DNA
from either peripheral blood lymphocytes or lymph nodes. DNA
extraction was performed according to standard procedures by proteinase
K digestion (United States Biochemicals) and phenol±chloroform extrac-
tion (United States Biochemicals).
In most patients with Sezary syndrome (15 of 18) and in three with
tumor stage mycosis fungoides T cell clones were detected in skin,
blood, lymph nodes, and bone marrow aspirates. In these patients no
DNA was available without a T cell clone and normal DNA was
obtained by isolating CD8-positive cells from peripheral blood lympho-
cytes as previously described (Scarisbrick et al, 2001).
LOH analysis Tumor and normal DNA samples from individual
patients were analyzed for allelic loss using oligonucleotide primers for
several microsatellite markers. Markers were chosen ¯anking the P15 and
P16 genes. These genes are intricately linked on 9p21 and a further
marker in between these genes was also selected for analysis. This
included primers (from telomere to centromere) D9S171, p15/p16, and
a-interferon (a-IFN) (Heyman et al, 1996). Figure 1 shows the relative
position of these markers to the P14, P15, P16, methylthioadenosine
(MTAP), and the IFN cluster genes on 9p21. DNA samples and
matched normal controls from individual patients were analyzed for
LOH as previously described (Scarisbrick et al, 2000, 2001).
Determination of LOH All samples showing two distinct allelic bands
in normal DNA were considered to be informative. Samples that
produced a single allelic band in normal DNA or failed to amplify for a
given microsatellite marker were scored as noninformative.
The signal intensities for all informative samples were examined
visually by two independent observers without knowledge of clinical
details. LOH was scored as positive when a clear reduction in signal
intensity was detected in one of the alleles in tumor DNA compared to
the same allele in the paired normal DNA. In instances where more than
one band was present within each allele the exact position of each allele
was decided by comparing the banding pattern in all samples analyzed
with the same marker and selecting the most consistent pattern: the two
alleles were identi®ed as two groups of bands of similar number and
signal intensity (Scarisbrick et al, 2001). In order to quantify signal
intensities we also analyzed samples using a scanning densitometer with
Image Quant software (Amersham Pharmacia); a reduction in signal
intensity of more than 50% in one of the alleles in the tumor DNA
compared to the paired normal DNA was de®ned as LOH. Many
samples showed a reduction in signal intensity approaching 90%.
Densitometry was undertaken on all samples where the reduction in
signal intensity was dif®cult to quantify visually. Samples showing LOH
were subjected to repeat ampli®cation and analysis for con®rmation
when suf®cient material was available.
Analysis for homozygous deletions Samples with LOH at
microsatellite markers ¯anking the P15 and P16 gene region (p15/p16
and a-IFN for the P16 gene and p15/p16 and D9S171 for the P15
gene) were examined for homozygous deletion using the P16 intragenic
marker D9S1747 and the P15 intragenic marker D9S1748. PCR were
performed as for LOH analysis. Twenty-®ve cycles were performed
annealing at 55°C±60°C depending on the Tm of the primer pairs.
Radiographs were then analyzed for LOH. Any sample with LOH at
both markers ¯anking either P15 or P16 genes, which demonstrated
retention of heterozygosity at the intragenic microsatellite marker (due to
the presence of wild-type reactive cells within biopsy material), was
considered to have homozygous deletion of the appropriate gene.
Single strand conformation polymorphism (SSCP)
analysis Samples demonstrating allelic loss on 9p were also analyzed
for P15 and P16 gene mutations. Five exonic primer pairs spanning all
three exons of the P16 gene and both exons of the P15 gene (Heyman
et al, 1996) were ampli®ed by PCR prior to SSCP analysis on
nondenaturing polyacrylamide gels.
The PCR was performed as for LOH analysis. 6% dimethyl sulfoxide
(BDH Laboratories, U.K.) was added for the primer pairs of exon 1 of
the P16 gene. Thirty cycles were performed annealing at 55°C±65°C
depending on the Tm of the primer pairs.
PCR products were diluted 2-fold with stop solution [95% formamide
(BDH Laboratories), 20 mM ethylenediamine tetraacetic acid (BDH
Laboratories), 0.05% xylene cyanol FF (BDH Laboratories), and 0.05%
bromophenol blue (Sigma, U.K.)] and denatured for 10 min at 95°C
prior to rapid cooling in a dry ice ethanol bath. Samples were loaded in
turn onto nondenaturing 6% polyacrylamide gels (Gibco BRL, U.K.)
containing 0%, 5%, and 10% glycerol (Sigma) and electrophoresed using
an S2 sequencing gel apparatus (Gibco BRL) at 4 W overnight.
Figure 1. Diagram showing approximate positions of
microsatellite markers in relation to the P15 and P16 genes on
9p21.
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Polyacrylamide gels were dried and exposed to autoradiography (Genetic
Research Instrumentation, U.K.). Radiographs were examined for
conformational change as shown by a band shift in tumor DNA
compared to wild-type.
Sequence analysis Abnormal band shifts detected by SSCP-PCR
were sequenced. Each abnormal band shift was cut directly from the
dried gel. DNA was recovered by boiling the gel with water. DNA
eluted in this way was re-ampli®ed using a 5¢ biotinylated primer and
the corresponding unmodi®ed 3¢ primer. Successful reampli®cation was
determined by electrophoresis on 2% agarose gels prior to sequencing.
The DNA strands were then separated using a magnetic rack (Dynal,
Norway), which immobilizes the biotinylated 5¢ DNA strand allowing
the removal of the 3¢ DNA strand. The single stranded 5¢ DNA was
then sequenced using a Sequenase Version 2 DNA sequencing kit
(United States Biochemicals, U.K.) with S35 (Amersham Pharmacia).
Products were then analyzed by electrophoresis on denaturing 6%
polyacrylamide gels with 7 M urea (United States Biochemicals, U.S.A.).
Methylation analysis of CpG islands Samples were analyzed for
methylation of the 5¢-CpG islands within exon 1 of the P15 and P16
genes, which contain the promoter regions, using methylation-speci®c
PCR (Herman et al, 1995). This technique requires DNA to be
chemically modi®ed by sodium bisul®te prior to PCR with primers for
both methylated and unmethylated products. Methylated cytosine bases
are protected from bisulfate conversion to uracil and therefore do not
amplify with primers for unmethylated DNA (Heyman et al, 1996).
RAJI cell line (European Tissue Culture Center, U.K.) was grown in
RPMI 1640 (Life Technologies, U.K.) with 10% heat-inactivated fetal
bovine serum (Helena Technologies, U.K.) supplemented with 2 mM
glutamine (Life Technologies). Cells were harvested by trypsinization and
DNA was extracted, as previously described, during the logarithmic
growth phase. The RAJI cell line is hypermethylated at the P15 and P16
gene promoter and was therefore used as a positive control.
DNA samples were subjected to bisul®te modi®cation as previously
described (Herman et al, 1995). Methylation-speci®c PCR was then
performed incorporating radioactivity (P33) using two primer pairs for
unmethylated DNA (P16U and P15U) and three primer pairs for
methylated DNA, two for methylation of the ®rst exon of P16 (P16M
and P16M2) and one for methylation of the ®rst exon of the P15 gene
(P15M). PCR products were electrophoresed on denaturing 6%
polyacrylamide gels for 2±3 h at 35 W. Autoradiographs were examined
for PCR ampli®cation products with both methylated and unmethylated
primers for each sample. Any sample that ampli®ed with the unmethy-
lated primers was considered to have undergone bisul®te modi®cation
and was assumed to be informative (the presence of wild-type DNA
from reactive cells presumably accounting for nonmethylated DNA in
biopsy material). On each gel using the methylated primers the RAJI
PCR product and at least one informative sample was sequenced to
ensure it was the correct product. All informative samples that ampli®ed
with the methylated primers for either the P15 or P16 gene were scored
as hypermethylated for the appropriate gene.
Immunohistochemical methods Immunohistochemical staining was
performed manually on freshly cut 4 mm sections of formalin-®xed
paraf®n-embedded tissue on lesional skin from the same biopsy that
DNA was extracted for this study. In brief, sections were melted and
dewaxed and endogenous peroxidase was blocked by incubation with 3%
hydrogen peroxide (Sigma) in methanol (Sigma) at room temperature.
Antigen retrieval was performed by heat-mediated pretreatment using
10 mmol per l sodium citrate buffer (Sigma) at pH 6.0 and microwaved
at 650±750 W for 10±15 min. A streptavadin±biotin labeled horseradish
peroxidase procedure was then employed in all cases.
Immunohistochemical staining using primary mouse monoclonal anti-
bodies against p15 and p16 (Santa Cruz Technology, CA) at a dilution
of 1:250 was performed as previously described (Elenitoba-Johnson et al,
1998). An irrelevant antibody of the same subclass was used as a negative
control. Suf®cient archival material was available for analysis from 20 of
43 patients with P15 gene abnormalities and 17 of 34 patients with P16
gene abnormalities. In addition 10 samples without any detectable gene
abnormalities were also analyzed,
Slides were assessed by two independent observers without knowledge
of clinical details or molecular studies. p15 and p16 are nuclear proteins
and nuclear reactivity with the antibody was considered as a positive
signal for protein expression. Inactivation of P15 and P16 genes have
been shown to be associated with absent protein expression (Reed et al,
1996; Pinyol et al, 1998; Villuendas et al, 1998). The staining of basal
and suprabasal keratinocytes was used as an internal control. The
percentage of mononuclear cells showing absent nuclear reactivity was
assessed as follows: <25%, 25%±50%, 50%±75% or >75%.
RESULTS
LOH Seventy-three of the samples were informative for at least
one of the three microsatellite markers. LOH was observed in 18
samples (25%) at one or more of the markers. In 16 samples this
included LOH with the p15/p16 microsatellite marker and in the
other two samples there was loss with the a-IFN microsatellite
marker and retention of heterozygosity with the p15/p16 marker.
The degree of reduction in allelic signal intensity was frequently
greater than 50% and in some instances approached 100%.
Examples of allelic loss are shown in Fig 2.
Twelve of the 58 patients with mycosis fungoides (21%)
demonstrated LOH. This included seven of 32 patients (22%)
with early cutaneous stages of mycosis fungoides (two of 14 with
T1 and ®ve of 18 with T2 stage) and ®ve of 25 patients (20%) with
advanced cutaneous disease (four of 20 with T3 and one of ®ve
with T4 stage). LOH was also identi®ed in six of 16 patients with
Sezary syndrome (38%).
These microsatellite markers on 9p were speci®cally chosen
because of their proximity to the P15 and P16 tumor suppressor
genes (9p21) and LOH at these markers suggests that one allele of
either gene has been deleted (Heyman et al, 1996).
Homozygous deletion Two patients demonstrated LOH in
both markers ¯anking the P16 gene (p15/p16 and a-IFN) and
were analyzed for homozygous deletions using the intragenic
microsatellite marker D9S1747. Homozygous deletion of the P16
gene was not identi®ed in either sample using this approach. LOH
at both markers ¯anking the P15 gene were not found in any
Figure 2. Examples of radiographs showing loss of
heterozygosity on 9p21. Microsatellite analysis using different markers
produces different allelic banding patterns. LOH needs to be assessed in
comparison with other samples using the same marker.
Figure 3. Conformational band shifts in exon 3 of the P16 gene.
SSCP gel showing abnormal bands in two patients.
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patient sample and so we were unable to look for homozygous
deletions of the P15 gene using this method.
Mutational analysis of the P15 and P16 genes All 18 patient
samples showing LOH on 9p21 were screened for point mutations,
small deletions, and insertions in exons 1 and 2 of the P15 gene and
exons 1, 2, and 3 of the P16 gene using SSCP-PCR. No abnormal
band shifts were detected in either exon of the P15 gene. Three
conformational band shifts were detected in exon 3 of the P16 gene
(Fig 3). Suf®cient material for sequence analysis was available in
two of these patients and both showed a single base pair substitution
residing in the 3¢ untranslated region of the P16 gene, which was
present in both tumor and normal DNA, consistent with a
polymorphism; one represented a previously described
polymorphism, C to T base transition at nucleotide 580 (Holland
et al, 1995), and the other a C to A base transversion at nucleotide
613 (Fig 4), which to our knowledge has not previously been
reported (http://www.ncbi.nlm.gov/SNP). Both SSCP analysis
and direct sequencing demonstrated residual normal bands
representing the normal allele suggesting that both patients were
heterozygous for these polymorphisms.
In order to determine the frequency of these polymorphisms in
our cohort of patients the remaining 58 patients were subjected to
SSCP-PCR analysis of exon 3 of the P16 gene. Abnormal band
shifts were detected in a further ®ve patients. Sequence analysis was
performed and three further patients demonstrated the same C to T
base change at nucleotide 580. This represents a T allele frequency
at nucleotide 580 of at least 2.6% (four of 152 alleles). The C613A
polymorphism was not detected in any other patient sample.
Methylation status of P15 and P16 genes DNA modi®cation
by bisul®te was complete in 66 patient samples as detected by DNA
ampli®cation with the primer set for modi®ed unmethylated DNA.
Thirty-six of these samples (55%) also ampli®ed with at least one of
the primer sets for methylated DNA. Figure 5 shows a radiograph
demonstrating ampli®cation with the P15M primer in ®ve of 10
patients. Thirty patient samples (45%) ampli®ed with the
methylated primers for exon 1 of the P15 gene (P15M)
(Table I). This included 12 of 30 patients (40%) with early
cutaneous stages of mycosis fungoides (eight of 14 with T1 and four
of 16 with T2 stage disease), 13 of 24 patients (54%) with advanced
cutaneous disease (11 of 19 with T3 and two of ®ve with T4 stage
disease), and ®ve of 12 patients with Sezary syndrome.
Nineteen patient samples (29%) ampli®ed with the methylated
primers for exon 1 of the P16 gene (Table I), all with mycosis
fungoides ± 10 of 30 patients (33%) with early cutaneous disease
(®ve of 14 with T1 and ®ve of 16 with T2 stage) and seven of 24
patients (29%) with advanced mycosis fungoides (®ve of 19 with T3
and two of ®ve with T4 stage). Methylation of the P16 gene was
not identi®ed in any of the 12 patients with Sezary syndrome.
Immunohistochemical analysis Twenty patients with P15
gene abnormalities were analyzed for p15 protein expression and 17
patients with P16 gene abnormalities for p16 protein expression
using immunohistochemical studies with p15 and p16 monoclonal
antibodies, respectively. The molecular abnormalities detected in
these patients are shown in Table I. Ten patients without
detectable abnormalities on 9p21 were also studied.
Altered p15 protein expression was found in 17 of 20 patients
and altered p16 protein expression in 10 of 17 patients with gene
abnormalities (Table I). All patient samples analyzed without any
detectable gene abnormalities showed normal protein expression.
In all six samples with biallelic gene abnormalities (three with
LOH and P15 methylation and three with LOH and P16
methylation) absent nuclear reactivity was detected in 50%±75%
of mononuclear cells (Fig 6) but no samples had absent protein
expression in all mononuclear cells. The remaining patients with
abnormal protein expression and monoallelic gene abnormalities
showed absent nuclear reactivity in less than 50% of mononuclear
cells (Table I).
DISCUSSION
Overall, abnormalities on 9p21 were detected in 63% of patients,
including abnormalities involving the P15 gene in 57% and of the
P16 gene in 45% of patients, with similar rates detected in all
cutaneous stages of mycosis fungoides and Sezary syndrome.
Biallelic abnormalities of the P15 gene and P16 gene were
identi®ed in nine and six patients, respectively. The most common
abnormality was promoter methylation, which was identi®ed in
55% of patients. Allelic loss at the loci of the P15 and P16 genes was
detected in 25%. Homozygous deletion was not identi®ed in any
patient and no intragenic mutations of either gene were detected.
Aberrant P15 protein expression correlated with gene abnormalities
in 85% of patients and aberrant P16 gene expression in 59%
suggesting gene inactivation.
LOH on 9p21 was detected in 21% of patients with mycosis
fungoides, at a similar frequency in both early and late disease, and
in 38% with Sezary syndrome. These microsatellite markers on
9p21 were speci®cally chosen because of their proximity to the P15
and P16 genes and LOH at these markers implies that one allele of
either gene has been deleted (Heyman et al, 1996). Homozygous
deletion is a common mechanism of P15 and P16 gene inactivation
and has been reported in patients with T cell leukemia (Quesnel et
al, 1995; Rasool et al, 1995; Takeuchi et al, 1995) as well as a subset
of patients with non-Hodgkin's lymphoma (Freyling et al, 1995;
Gombart et al, 1995; Koduru et al, 1995; Drexler, 1998) where it
may be associated with high grade disease (Pinyol et al, 1997, 1998;
Elenitoba-Johnson et al, 1998). These genes are often co-deleted in
hematologic malignancies, although cytogenetic and molecular
studies have found that the P16 gene is more frequently deleted
than the P15 gene (Herbert et al, 1994; Dreyling et al, 1995; Otsuki
et al, 1995). We analyzed two samples with LOH at markers
¯anking the P16 gene using an intragenic microsatellite marker.
This technique has been shown to accurately detect homozygous
deletion of these genes when compared to southern blot and FISH
Figure 4. Cytosine (C) to adenosine (A) substitution at nucleotide
613 of the P16 gene. Polyacrylamide gel showing sequencing of the
negative strand of P16 exon 3; both guanine (G) and thymidine (T)
bands are present with a reduced signal intensity at 613 indicating that
the sample is heterozygous for this C(613)A polymorphism.
Figure 5. Aberrant methylation of the P15 gene. Polyacrylamide
gel showing ampli®cation of DNA extracted from the RAJI cell line
with primers for methylated P15 gene promoter in ®ve of 10 patients
with CTCL (patients 1, 4, 7, 9, and 10).
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analysis (Cairns et al, 1995) and has previously been used to detect
homozygous deletions of the PTEN gene in a subset of patients
with mycosis fungoides (Scarisbrick et al, 2000). Homozygous
deletion of the P16 gene was not detected in either sample using
this approach, however. The smallest deleted region on 9p21
commonly involves a 120 kb region from the 3¢ MTAP gene to the
P15 gene (Fig 1) but larger homozygous deletions are common
and frequently encompass the entire IFN gene cluster as well as the
P15 and P16 genes (Dreyling et al, 1995; Olopade et al, 1995). Such
large homozygous deletions would not be detected using our
methodology. Additional methods for detecting larger homozygous
deletions such as comparative multiplex PCR or southern blot
analysis would determine if the p15 and p16 genes are
homozygously deleted in CTCL (Cairns et al, 1994; Ogawa et al,
1994; Kim et al, 1997).
P16 gene mutations are found in a third of patients with familial
melanoma as well as in patients with sporadic pancreatic malig-
nancies but have only rarely been identi®ed in nodal lymphomas, in
keeping with our ®ndings (Otsuki et al, 1995; Gombart et al, 1995;
Pinyol et al, 1997). It is possible that mutations may have been
missed as samples were analyzed using SSCP-PCR, which is only
capable of detecting those gene mutations that result in an abnormal
electrophoretic pattern. Direct sequencing of the entire gene would
detect rare single base substitutions not identi®ed by SSCP-PCR
but insuf®cient DNA was available for this approach.
A previously reported P16 gene polymorphism, C580T, was
found at a frequency of 2.6% in our cohort, which is lower than the
10% quoted in the literature (Holland et al, 1995, 1999). A novel
polymorphism (C613A) was detected in one further patient. These
single nucleotide substitutions all occurred within the 3¢ untrans-
Table I. Molecular abnormalities on 9p21 in 48 of 76 patients with CTCLa
Molecular abnormalities








(no. patients &% negative cells)
No. analyzed for
p16 expression
Abnormal p16 expression (no.
patients & % negative cells)
LOH (only) 10 3 1 (< 25%) 3 1 (< 25%)
LOH + P15M 5 3 3 (1 > 75%, 2 = 50±75%) 1 0
LOH + P16M 3 3 3 (both 50±75%)
LOH + P15M & P16M 0 0 ±
P15M only 14 10 9 (5 = 50±75%, 4 = 25±50%) 0 ±
P16M only 5 3 3 (all < 25%)
P15M + P16M 11 4 4 (2 > 75%, 2 = 50±75%) 7 3 (all < 25%)
Total 48 20 17 17 10
aP15 and P16 gene expression was analyzed in 20 and 17 patients and was abnormal in 17 (85%) and 10 patients (59%), respectively. The percentage of mononuclear cells
with absent nuclear staining was assessed as follows: <25%, 25%, ±50%, 50%±75%, >75%.
Figure 6. Immunohistochemical staining with a p16 monoclonal antibody in two patients with biallelic P16 gene abnormalities (LOH
and p16 gene promoter hypermethylation). The photomicrograph on the left shows normal nuclear staining of the basal keratinocytes (positive
internal control) and a dermal mononuclear cell in®ltrate with absent staining in 50%±75% of cells; in particular the larger atypical cells are negative.
The photomicrograph on the right shows a population of epidermotropic atypical mononuclear cells. These cells are negative for p16.
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lated region, which is a noncoding region and does not result in an
amino acid change. The functional role of the 3¢ untranslated
region of the P16 gene has still to be determined, however, and
may contain sequence elements crucial for gene regulation and
expression (Pesole et al, 2000).
Several studies have examined the methylation status of the P15
and P16 genes in different forms of lymphoma/leukemia (Herman
et al, 1997; Martinez-Delgado, 1997; Martinez-Delgado et al, 1998;
Baur et al, 1999). A study of 56 cases of non-Hodgkin's lymphoma,
analyzed by both restriction-enzyme-related PCR and methyla-
tion-speci®c PCR, detected high rates of aberrant methylation of
P15 and P16 genes in both B and T cell lymphomas particularly in
high grade disease (Baur et al, 1999). A more recent study of 64
cases of acute leukemia found methylation of the P15 and P16 gene
in 40% and 42% of cases, respectively, with low frequencies of
mutations and deletions (Guo et al, 2000). In our study methylation
of the P15 gene was more frequent than of the P16 gene with rates
of 45% and 29%, respectively. Methylation of both genes was found
in 17% of patients and selective P15 and P16 promoter methylation
in 29% and 12% of patients, respectively. In Sezary syndrome
selective P15 gene methylation was present in 42% of patients and
no cases had alteration of the P16 gene promoter.
A small study by Navas et al (2000) of nine patients with patch/
plaque and tumor stage mycosis fungoides found alterations in four
of nine plaques (hypermethylation in three samples and allelic loss
in one) and seven of nine tumors (hypermethylation in ®ve samples
and allelic loss in three samples). No point mutations were
identi®ed. Peris et al (1999) examined mRNA expression in 20
patients with mycosis fungoides by reverse transcription PCR and
dot blot hybridization. P16 mRNA expression was undetectable in
®ve patients, intermediate in 13, and normal in two patients. DNA
mutational analysis revealed no alterations in the six patients
analyzed but methods to detect LOH and hypermethylation were
not employed. Absent mRNA expression was found to correlate
with absent p16 protein expression, however. No direct correlation
between clinicopathologic and molecular ®ndings was evident.
In our study P15 and P16 gene expression was studied in half of
the patients with detecteble gene abnormalities and was abnormal
in 85% and 59% of patients, respectively, including all six with
biallelic gene abnormalities; absent protein expression was found in
a subset of the mononuclear cells in these patients with 50%±75% of
dermal mononuclear cells showing absent nuclear reactivity. This
contrasts with ®ndings in other studies in which P15 and P16 gene
abnormalities were associated with absent protein expression in
almost all cells (Reed et al, 1996; Pinyol et al, 1998; Villuendas et al,
1998). This difference is presumably explained in mycosis
fungoides, however, by the presence of both neoplastic and
reactive mononuclear cells within the dermis. Alternatively either
P15 or P16 gene promoter hypermethylation may cause a gene
dosage effect or gene abnormalities may be restricted to a
subpopulation of tumor cells. Fourteen of 17 patients with
monoallelic abnormalities of the P15 gene and seven of 14 with
monoallelic abnormalities of the P16 gene also showed altered
protein expression with absent nuclear reactivity in 25%±50% of
mononuclear cells. This suggests that in these patients a
subpopulation of tumor cells may have an undetected gene
abnormality involving the remaining allele. The other 10 patients
with monoallelic gene abnormalities showed normal protein
expression implying that in these cases the other allele was
functional. Furthermore all 10 patients without detectable gene
abnormalities had normal protein expression.
Inactivation of the P16 gene is not speci®c to lymphoid
malignancies and as previously mentioned germline mutations may
be found in familial melanoma as well as pancreatic cancer. P16
gene abnormalities have also been identi®ed in other solid
malignancies: e.g., in nonsmall cell lung cancer homozygous
deletion and hypermethylation have been detected in 31% and 21%
of cases with only occasional point mutations and these
abnormalites correlated with absent protein expression (Sanchez-
Cespedes et al, 1999). In oligodendromas homozygous deletion of
the P16 gene is frequent but hypermethylation may not be found
(Bortolotto et al, 2000), whereas in cholangiosarcoma associated
with primary sclerosing cholangitis both allelic loss and hyper-
methylation have been identi®ed and associated with absent protein
expression (Ahrendt et al, 1999). Several mechanisms for P16 gene
inactivation clearly exist; however, no disease-speci®c pattern of
inactivation is apparent.
Further analysis of P15 and P16 gene function is important to
determine the transcriptional activity of these genes in different
cutaneous stages of mycosis fungoides. Interestingly another tumor
suppressor gene on 9p21, the P14 gene, has recently been
characterized. This gene has a separate promoter and ®rst exon,
designated exon 1b (Fig 1), which splices into exon 2 of the P16
gene in an alternative reading frame resulting in a distinct transcript
(Quelle et al, 1995). The p14 protein can interact with MDM2
protein preventing its degradation and therefore allowing accumu-
lation of p53 (Pomerantz et al, 1998; Zhang et al, 1998). P14 gene
methylation is a common event in colorectal malignancy and is
independent of the methylation status of the P16 gene (Esteller et al,
2000). Although P14 gene promoter hypermethylation was not
detected in 56 cases of non-Hodgkin's lymphoma (Baur et al,
1999), deletions on 9p21 would frequently encompass the P14 gene
and SSCP analysis of exon 1b and the methylation status of this
gene would be appropriate. Insuf®cient material was available for
analysis in this study, however.
P15 and P16 gene abnormalities are frequent in all cutaneous
stages of CTCL and commonly involve either allelic loss and/or
promoter hypermethylation. In a subset of patients including those
with biallelic events p15 and p16 protein expression was abnormal.
This suggests that both P15 and P16 gene inactivation may be an
early event in the pathogenesis of mycosis fungoides unlike P53
gene inactivation, which is found in advanced disease (Lauritzen et
al, 1995; Marks et al, 1996; McGregor et al, 1999).
REFERENCES
Ahrendt SA, Eisenberger CF, Yip L, Rashid A, Chow JT, Pitt HA, Sidransky D:
Chromosome 9p21 loss and p16 inactivation in primary sclerosing cholangitis-
associated cholangiocarcinoma. J Surg Res 84:88±93, 1999
Baur AS, Shaw P, Burri N, Delacretaz F, Bosman FT, Caubert P: Frequent
methylation silencing of p15 and p16 in B-cell and T-cell lymphomas. Blood
94:1773±1781, 1999
Berger R, Baranger L, Bernheimm A, Valensi F, Flandrin G: Cytogenetics of T-cell
malignant lymphoma: report of 17 cases and review of the chromosomal
breakpoints. Cancer Genet Cytogenet 36:123±130, 1988
Boni R, Xin H, Kamarashev J, et al: Allelic deletion at 9p21±22 in primary cutaneous
CD30+ large cell lymphoma. J Invest Dermatol 115:1104±1107, 2000
Bortolotto S, Chiado-Piat L, Cavalla P, Bosone I, Chio A, Mauro A, Schiffer D:
CDKN2A/p16 inactivation in the prognosis of oligodendrogliomas. Int J
Cancer 88:554±557, 2000
Cairns P, Tokino K, Eby Y, Sidransky D: Homozygous deletions of 9p21 in primary
human bladder tumors detected by comparative multiplex polymerase chain
reaction. Cancer Res 54:1422±1424, 1994
Cairns P, Polascik TJ, Eby Y, et al: Frequency of homozygous deletion at p16/
CDKN2 in primary human tumours. Nat Genet 11:210±212, 1995
Drexler HG: Review of alterations of the cyclin dependent kinases inhibitor INK4
family genes p15, p16, p18 and p19 in human leukaemia-lymphoma cells.
Leukaemia 12:845±859, 1998
Dreyling MH, Bohlander SK, Le Beau MM, Olapade OI: Re®ned mapping of
genomic rearrangements involving the short arm of chromosome 9 in acute
lymphoblastic leukaemias and other haematologic malignancies. Blood
86:1931±1938, 1995
Edelson RL: Cutaneous T-cell lymphoma: mycosis fungoides, Sezary syndrome, and
other variants. J Am Acad Dermatol 2:89±106, 1980
Elenitoba-Johnson KS, Gascoyne RD, Lim MS, Chhanabai M, Jaffe ES, Raffeld M:
Homozygous deletions at chromosome 9p21 involving p16 and p15 are
associated with histologic progression in follicle center lymphoma. Blood
91:4677±4685, 1998
Esteller M, Tortola S, Toyota M, Capella G, Peinado MA, Baylin SB, Herman JG:
Hypermethylation of p14 is independent of p16 methylation and p53
mutational status. Cancer Res 60:129±133, 2000
Fraser-Andrews E, Woolford AJ, Russell-Jones R, Seed PT, Whittaker SJ: Detection
of a peripheral blood T cell clone is an independent prognostic marker in
mycosis fungoides. J Invest Dermatol 114:117±121, 2000
Gombart AF, Morosetti R, Miller CW, Said JW, Koef¯er HP: Deletions of the
cyclin-dependant inhibitor genes p16 and p15 in non-Hodgkin's lymphoma.
Blood 86:1534±1539, 1995
Gonzalez-Zulueta M, Bender CM, Yang AS, Nguyen T, Beart RW, Van Tornout
JM, Jones PA: Methylation of the 5¢-CpG island of the p16/CDKN2 tumor
498 SCARISBRICK ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
suppressor gene in normal and transformed human tissues correlates with gene
silencing. Cancer Res 55:4531±4535, 1995
Guo SX, Taki T, Ohnishi H, et al: Hypermethylation of p16 and p15 genes and RB
protein expression in acute leukemia. Leuk Res 24:39±46, 2000
Herbert J, Cayeula JM, Berkeley J, Sigaux F: Candidate tumour suppressor gene
MTS1 (p16INK4A) and MTS2 (p15INK4B) display frequent homozygous
deletions in primary cells from T- but not B-cell lineage acute lymphoblastic
leukaemias. Blood 84:4038±4044, 1994
Herman JG, Merlo A, Mao L, et al: Inactivation of the CDKN2/p16/MTS1 gene is
frequently associated with aberrant DNA methylation in all common human
cancers. Cancer Res 55:4525±4530, 1995
Herman JG, Civin CI, Issa J-PJ, Collector MI, Sharkis SJ, Baylin SB: Distinct patterns
of inactivation of p15 (INK4B) and p16 (INK4A) characterize the major types
of hematological malignancies. Cancer Res 57:837±841, 1997
Heyman M, Rasool O, Borgonov-Brandter L, et al: Prognostic importance of
p15INK4B and p16INK4 gene inactivation in childhood acute lymphocytic
leukemia. J Clin Oncol 14:1512±1520, 1996
Holland EA, Beaton SC, Becker TM: Analysis of the P16 gene, CDKN2, in 17
Australian melanoma kindreds. Oncogene 11:2289±2294, 1995
Holland EA, Schmid H, Kefford RF, Mann GJ: CDKN2A (P16 INK4a) and CDK4
mutational analysis in 131 Australian melanoma probands: effect of family
history and multiple primary melanomas. Genes Chromosomes Cancer 25:339±
348, 1999
Hussussian CJ, Struewing JP, Goldstein AM, et al: Germline p16 mutations in familial
melanoma. Nat Genet 8:15±21, 1994
Kamb A, Gruis NA, Weaver-Feldhaus J, et al: A cell cycle regulator potentially
involved in genesis of many tumor types. Science 264:436±440, 1994
Karenko L, Kahkonen M, Hyytinen E, Lindlof M, Ranki A: Notable losses at speci®c
regions of chromosome 10q and 13q in the Sezary syndrome detected by
comparative genomic hybridization. J Invest Dermatol 12:392±395, 1999
Kim SK, Ro JY, Kemp BL, et al: Identi®cation of three distinct tumour suppressor
loci on the short arm of chromosome 9 in small cell lung cancer. Cancer Res
57:400±403, 1997
Koduru PRK, Zariwala M, Soni M, Gong JZ, Xiong Y, Broome JD: Deletion of
cyclin dependent kinase 4 inhibitor genes p15 and p16 in non-Hodgkin's
lymphoma. Blood 86:2900±2905, 1995
Lamberg SI, Green SB, Byar DP, et al: Clinical staging for cutaneous T-cell
lymphoma. Ann Int Med 100:187±192, 1984
Lauritzen A, Vejlsgaard G, Hou-Jensen K, Ralfkier E: p53 protein expression in
cutaneous T-cell lymphomas. Br J Dermatol 133:32±36, 1995
Marks D, Vonderheid E, Kurz B, et al: Analysis of p53 and mdm-2 expression in 18
patients with Sezary syndrome. Br J Haematol 92:890±899, 1996
Martinez-Delgado Fernandez-Piqueras J: Hypermethylation of a 5¢-CpG island of
p16 is a frequent event in non-Hodgkin's lymphoma. Leukaemia 11:425±428,
1997
Martinez-Delgado Robledo M, Arranz E: Hypermethylation of p15/ink4b/MTS2
gene is differentially implicated amoung non-Hodgkin's lymphoma. Leukaemia
12:937±941, 1998
McGregor JM, Crook T, Fraser-Andrews EA, Rozycka M, Crossland S, Whittaker
SJ: Spectrum of p53 gene mutations suggests a possible role for ultraviolet
radiation in the pathogenesis of advanced cutaneous lymphomas. J Invest
Dermatol 112:317±321, 1999
Merlo A, Herman JG, Mao L, et al: 5¢-CpG island methylation is associated with
transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in
human cancers. Nat Med 1:686±692, 1995
Navas IC, Oritz-Romero PL, Villuendas R, et al: p16 gene alterations are frequent in
lesions of mycosis fungoides. Am J Pathol 1565±1572, 2000
Ogawa S, Hirano N, Sato N, et al: Homozygous loss of the cyclin-dependent kinase
4-inhibitor (p16) gene in human leukemias. Blood 84:2431±2435, 1994
Olopade OI, Pomykala HM, Hagos F, et al: Construction of a 2.8-megabase yeast
arti®cial chromosome contig and cloning of the human methylthioadenosine
phosphorylase gene from the tumor suppressor region on 9p21. Proc Natl Am
Soc 92:6489±6493, 1995
Otsuki T, Clark HM, Wellman A, Jaffe ES, Raffeld M: Involvement of CDKN2
(p16INK4A/MTS1) and p15INK4B/MTS2 in human leukaemias and
lymphomas. Cancer Res 55:1436±1440, 1995
Peris K, Stanta G, Fargnoli MC, Bonin S, Felli A, Amantea A, Chimenti S: Reduced
expression of CDKN2a/P16INK4a in mycosis fungoides. Arch Dermatol Res
291:207±211, 1999
Pesole G, Liuni S, Grillo G, Licciulli F, Larizza A, Makalowski W, Saccone C:
UTRdb and UTR site: specialized databases of sequences and functional
elements of 5¢- and 3¢-untranslated regions in eukaryotic mRNAs. Nuc Acids
Res 28:193±196, 2000
Pinyol M, Hernandez L, Cazorla M, et al: Deletions and loss of expression of
p16INK4a and p21Waf1 genes are associated with aggressive variants of mantle
cell lymphomas. Blood 89:272±280, 1997
Pinyol M, Cobo F, Bea S, et al:. p16 (INK4a) gene inactivation by deletions,
mutations, and hypermethylation is associated with transformed and aggressive
variants of non-Hodgkin's lymphomas. Blood 91:2977±2984, 1998
Pomerantz J, Schreiber-Agus N, Liegeious NJ, et al: The Ink4a tumour suppressor
gene product, p19Arf, interacts with and neutralises MDM2¢s inhibition of
p53. Cell 92:713±723, 1998
Quelle DE, Zindy F, Ashmun RA, Scherr CJ: Alternative reading frames of the
INK4a tumour suppressor gene encode two unrelated proteins capable of
inducing cell cycle arrest. Cell 83:993±1000, 1995
Quesnel B, Preudhomme C, Phillipe N, et al: p16 gene homozygous deletions in
acute lymphoblastic leukaemia. Blood 85:657±663, 1995
Rasool O, Heymann M, Brandter LB, Liu Y, Grander D, Soderhall S, Einhorn S:
p15 and p16 gene inactivation in acute lymphocytic leukaemia. Blood 85:3431±
3436, 1995
Reed AL, Califano J, Cairns P, et al: High frequency of p16 (CDKN2/MTS-1/
INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res
56:3630±3636, 1996
Russell-Jones R, Whittaker S: TCR gene analysis in the diagnosis of Sezary
syndrome. J Am Acad Dermatol 41:254±259, 1999
Sanchez-Cespedes M, Reed AL, Buta M, et al: Inactivation of the INK4A/ARF
locus frequently coexists with TP53 mutations in non-small cell lung cancer.
Oncogene 18:5843±5849, 1999
Scarisbrick JJ, Woolford AJ, Russell-Jones R, Whittaker SJ: Loss of heterozygosity on
10q and microsatellite instability in advanced stages of primary cutaneous T-cell
lymphoma and possible association with homozygous deletion of PTEN. Blood
95:2937±2942, 2000
Scarisbrick JJ, Woolford AJ, Russell-Jones R, Whittaker SJ: Allelotyping in mycosis
fungoides and Sezary syndrome: common regions of allelic loss identi®ed on
9p, 10q and 17p. J Invest Dermatol, 2001
Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell-cycle control
causing speci®c inhibition of cyclin D/CDK4. Nature 366:704±707, 1993
Takeuchi S, Bartram CR, Seriu T, et al: Analysis of a family of cyclin-dependent
kinase inhibitors. p15/MTS2/INK4B, 16/MTS1/INK4A, and p18 genes in
acute lymphoblastic leukemia of childhood. Blood 86:755±760, 1995
Villuendas R, Sanchez-Beato M, Martinez JC, et al: Loss of p16/INK4A protein
expression in non-Hodgkin's lymphomas is a frequent ®nding associated with
tumor progression. Am J Pathol 153:887±897, 1998
Whittaker SJ, Smith NP, Russell-Jones R, Luzzatto L: Analysis of beta, gamma and
delta TCR genes in mycosis fungoides and Sezary syndrome. Cancer 68:1572±
1582, 1991
Willemze R, van Vloten WA, Hermans J, Damsteeg MJ, Meijer CJ: Diagnostic
criteria in Sezary's syndrome: a multiparameter study of peripheral blood
lymphocytes in 32 patients with erythroderma. J Invest Dermatol 81:392±397,
1983
Willemze R, Kerl H, Sterry W, et al: EORTC classi®cation for primary cutaneous
lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the
European Organization for Research and Treatment of Cancer. Blood 90:354±
371, 1997
Zackheim HS, Amin S, Kashani-Sabet M, McMillan A: Prognosis in cutaneous T-
cell lymphoma by skin stage: long-term survival in 489 patients. J Am Acad
Dermatol 40:418±425, 1999
Zhang Y, Xiong Y, Yarbrough WG: ARF promotes MDM2 degradation and
stabilises p53. ARF-INK4a locus deletion impairs both the Rb and p53 tumour
suppressor pathways. Cell 92:725±734, 1998
VOL. 118, NO. 3 MARCH 2002 P15 AND P16 ABNORMALITIES IN CTCL 499
